Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis. Stuve O, Hartung HP, Freedman M, Li D, Hemmer B, Kappos L, Rieckmann P, Montalban X, Ziemssen T, Selmaj K Mult Scler Relat Disord. 2014 Nov; 3(6):754-5. Epub 2014 Nov 21. PMID: 25891595. Abstract CommentRecommendBookmarkWatch